Orchard Therapeutics和Er Kim宣布合作，扩大土耳其和某些欧亚国家符合条件的患者获得Libmeldy的机会-动脉网

Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries

Orchard Therapeutics 等信源发布 2024-10-07 19:03



可切换为仅中文







PDF Version

PDF版本

ISTANBUL and LONDON, and BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe and Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced the companies have signed an exclusive distribution agreement to commercialize Libmeldy® (atidarsagene autotemcel), the only approved therapy for eligible children with early-onset metachromatic leukodystrophy (MLD).

。

Libmeldy aims to correct the underlying genetic cause of MLD, an ultra-rare, rapidly progressive, irreversible and ultimately fatal neurometabolic disease that affects approximately one in 100,000 live births based on existing literature. Under the agreement, Er-Kim will serve as the exclusive representative of Orchard to identify children eligible for treatment with Libmeldy in international markets across Turkey, Russia, Ukraine, and the Commonwealth of Independent States.

Libmeldy旨在纠正MLD的潜在遗传原因，MLD是一种超罕见，快速进展，不可逆且最终致命的神经代谢疾病，根据现有文献，其影响大约每100000例活产婴儿中就有一例。根据协议，Er Kim将担任Orchard的独家代表，在土耳其、俄罗斯、乌克兰和独立国家联合体的国际市场上确定有资格接受Libmeldy治疗的儿童。

Er-Kim will collaborate with Orchard Therapeutics to refer eligible children with early-onset MLD identified in these countries to an established European-based qualified treatment center. “The pharmaceutical and biotech industries have made notable strides in advancing gene therapies and we are thrilled to partner with Orchard Therapeutics to enable access to this important treatment in the region,” said Cem Zorlular, chief executive officer of Er-Kim.

Er Kim将与Orchard Therapeutics合作，将在这些国家发现的符合条件的早发性MLD儿童转诊至已建立的欧洲合格治疗中心。Er Kim首席执行官Cem Zorlular表示：“制药和生物技术行业在推进基因治疗方面取得了显著进展，我们很高兴与Orchard Therapeutics合作，使该地区能够获得这种重要的治疗方法。”。

“Libmeldy is a potentially transformative therapy for eligible children with early-onset MLD who previously had no approved treatment options beyond supportive and end-of-life care. We are looking forward to working with Orchard and our counterparts in these territories that we specialize in to furth.

“Libmeldy是一种潜在的变革性疗法，适用于符合条件的早发性MLD儿童，他们以前除了支持性和临终关怀外，没有批准的治疗选择。我们期待着与Orchard和我们专门从事这些领域的同行合作。

For Er-Kim

对于Er Kim

Rosalia Scampoli

罗莎莉亚·斯坎波利

Marketcom PR

Marketcom公关

+1 914 815-1465

rscampoli@marketcompr.com

For Orchard

用于果园

Benjamin Navon